StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

CRISPR Therapeutics's pe ratio was 20.4× on Jul 29, 2022, against 199.6× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jul 29, 202220.4×+4.5
2021Dec 31, 202115.9×−183.7
2020Oct 30, 2020199.6×–

More CRISPR Therapeutics figures

See a number that looks wrong?